Seres Therapeutics (MCRB) EBIT Margin: 2016-2025
Historic EBIT Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to -6,403.70%.
- Seres Therapeutics' EBIT Margin was N/A to -6,403.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -96,662.62%, marking a year-over-year change of. This contributed to the annual value of -154.44% for FY2023, which is 236961.00% up from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' EBIT Margin is -6,403.70%, which was down 214.92% from 5,572.49% recorded in Q1 2024.
- Seres Therapeutics' EBIT Margin's 5-year high stood at 5,572.49% during Q1 2024, with a 5-year trough of -57,850.00% in Q4 2023.
- Its 3-year average for EBIT Margin is -14,423.90%, with a median of -9,961.24% in 2023.
- As far as peak fluctuations go, Seres Therapeutics' EBIT Margin slumped by 5,767,246bps in 2023, and later soared by 1,909,127bps in 2024.
- Seres Therapeutics' EBIT Margin (Quarterly) stood at -684.56% in 2021, then surged by 50,702bps to -177.54% in 2022, then slumped by 5,767,246bps to -57,850.00% in 2023, then spiked by 1,909,127bps to 5,572.49% in 2024, then reached -6,403.70% in 2025.
- Its EBIT Margin was -6,403.70% in Q3 2025, compared to 5,572.49% in Q1 2024 and -57,850.00% in Q4 2023.